Gilead Sciences (NASDAQ:GILD) shares traded in the green on Tuesday, making it the seventh consecutive days of gains. The stock closed up 0.04% at $76.99.
GILD stock fell about 0.06% in the last 12 months. YTD, the stock is trading down about 5.1%, compared to the broader S&P 500 market which is up 17.81%.
Looking at Seeking Alpha’s Quant Ratings, this company has a Hold rating with a score of 3.27 out of 5.
When it comes to Wall Street analysis, 14 out of 30 analysts recommend a Hold, 8 recommend a Strong Buy, 7 recommend a Buy and 1 recommends a Strong Sell.
Gilead this month announced that the FDA approved its liver disease therapy Livdelzi (seladelpar), added with its recent buyout of CymaBay Therapeutics. It also raised its 2024 non-GAAP EPS guidance following Q2 results that beat on both lines.
Seeking Alpha analysts have a Buy rating on the company.
